By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel consensus is bearish, with concerns over the company's profitability, high valuation, and potential dilution risk from equity raises. The insider sale, while planned, is seen as a red flag given the company's recent run-up and persistent losses.
Risk: Potential dilution risk from equity raises in a tiny float, which could crush the multiple regardless of an immediate earnings beat.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Dennis Cho sold 14,205 shares on May 29, 2026, for a total transaction value of ~$991,000, at a reported price of $69.75 per share.
This transaction reduced Cho’s direct holdings from 134,299 shares to 120,094 shares.
This sale is the largest single disposition in Cho’s 54 recent sales, reflecting both available share capacity and the stock’s 131.5% one-year gain as of the transaction date.
Chief Legal Officer Dennis Cho reported the sale of 14,205 shares of Twist Bioscience Corporation (NASDAQ:TWST) on May 29, 2026, for a transaction value of approximately $991,000, according to a SEC Form 4 filing.
| Metric | Value | |---|---| | Shares sold (direct) | 14,205 | | Transaction value | $991,000 | | Post-transaction shares (direct) | 120,094 | | Post-transaction value (direct ownership) | $8.03 million |
Transaction value based on SEC Form 4 reported price ($69.75); post-transaction value based on holdings as valued using the May 29, 2026 close price.
How does the size of this sale compare to Dennis Cho’s historical trading activity?
This 14,205-share disposition is the largest single sale executed by Cho in the past two years, nearly 12 times the average sell-only trade size of 1,147 shares across his 54 sell events, and substantially larger than any prior transaction on record.What proportion of Cho’s holdings did this transaction represent, and how does that compare to recent periods?
The sale accounted for 10.58% of Cho’s direct holdings at the time, a material step-down from 134,299 to 120,094 shares, and contrasts with the smaller incremental sales that characterized most of his trading since January 2025.What is the context for the sale relative to recent stock performance and capacity?
As of the May 29, 2026 transaction date, Twist Bioscience shares had appreciated 131.5% over the prior year, and Cho’s remaining direct holdings now represent approximately 0.19% of outstanding shares, with ongoing selling cadence reflecting both reduced holdings capacity and sustained share price momentum.
| Metric | Value | |---|---| | Price (as of market close 2026-05-29) | $66.87 | | Market capitalization | $4.31 billion | | Revenue (TTM) | $409.48 million | | Net income (TTM) | ($81.28 million) |
Twist Bioscience Corporation is a leading synthetic biology company specializing in high-throughput DNA synthesis using a proprietary silicon-based platform. The company leverages its technology to provide scalable, cost-effective synthetic DNA products for research, diagnostics, and therapeutic development.
Strategic collaborations with major industry players and a focus on innovation position Twist Bioscience to address the growing demand for synthetic biology solutions across healthcare and biotechnology sectors.
The May 29 sale of Twist Bioscience stock by Chief Legal Officer Dennis Cho is not a cause for investor concern. It was executed as part of a prearranged Rule 10b5-1 trading plan, adopted in May of 2025. Such plans are often implemented by insiders to avoid accusations of trading based on insider information.
In addition, several of Cho’s other recent stock dispositions were to cover tax withholding obligations in connection with the vesting of restricted stock units. This combined with his remaining directly-held stake of 120,094 shares indicates he is not in a rush to dispose of his holdings.
The May 29 transaction came at a time when Twist Bioscience shares were skyrocketing. The stock eventually hit a 52-week high of $80.50 on June 4.
The share price of this biotech stock is up because of the company’s excellent business performance. Revenue grew a strong 19% year over year to $110.7 million in its fiscal second quarter ended March 31. Thanks to its fiscal Q2 results, Twist Bioscience raised its 2026 full-year guidance, forecasting sales growth of 17% to 19% year over year.
Before you buy stock in Twist Bioscience, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Twist Bioscience wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $443,191! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,258,838!
Now, it’s worth noting Stock Advisor’s total average return is 941% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of June 6, 2026. *
Robert Izquierdo has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Twist Bioscience. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"The insider sale signals a potential overhang and questions about sustained profitability, implying upside is contingent on earnings-driven re-rating rather than continued momentum."
The insider sale appears routine at first glance due to the 10b5-1 plan, but it raises red flags upon closer look. Twist’s insider ownership is now a tiny 0.19% of outstanding shares, creating a potential overhang if more insiders trim positions. The stock trades at a steep multiple given negative trailing earnings ($-81.3M TTM) and still relies on optimistic growth assumptions (17-19% revenue growth for 2026) to justify valuation. Despite a momentum run to a 52-week high, the core business remains unprofitable, and dilution risk from RSU vesting or future fundraising isn’t discussed by the article. A pullback could occur if growth slows or profitability doesn’t materialize.
Even with a 10b5-1 plan, a large insider sale after a run can signal waning confidence or liquidity needs; if more insiders follow, the stock could face meaningful downside beyond the momentum. The article glosses over potential RSU-related dilution and any upcoming financing needs.
"The CLO's largest-ever single disposition during a 131% rally indicates that management is aggressively harvesting gains, suggesting the stock’s valuation has outpaced its fundamental operational reality."
While the 10b5-1 plan provides a legal shield, framing this as 'no cause for concern' is naive. A 14,205-share dump—12x his average trade size—occurring just days before a 52-week high suggests an insider maximizing liquidity during a momentum-fueled blow-off top. TWST is trading at roughly 10x trailing revenue despite persistent net losses. While 19% top-line growth is respectable, it doesn't justify a $4.3B valuation for a company that hasn't achieved profitability. Investors should view this as a classic 'sell the news' signal; when the CLO liquidates a significant position during a parabolic run, they are signaling that the risk-reward skew has shifted unfavorably.
If the company is on the verge of a breakthrough in DNA data storage or a major pharma partnership, the CLO might simply be rebalancing a concentrated portfolio rather than signaling a lack of confidence in the underlying technology.
"The size of this single disposition after a 131% advance flags valuation risk even if the 10b5-1 label removes the most obvious red flag."
Cho's 14,205-share sale is the largest of his 54 transactions and represents 10.58% of direct holdings, executed after a 131.5% run-up to $66.87. While filed under a 2025 10b5-1 plan, the scale exceeds average trades by 12x and coincides with still-negative net income of $81M on $409M TTM revenue. Investors should note that planned sales do not preclude later price weakness if Q3 growth misses the newly raised 17-19% guidance or if synthetic DNA margins fail to expand enough to justify the $4.31B market cap.
The plan was adopted a full year earlier, making the May 29 timing mechanical rather than discretionary, and tax withholdings on RSUs explain many prior small sales.
"A CLO selling 10.58% of holdings at a 131.5% one-year peak in an unprofitable biotech with speculative revenue growth deserves more skepticism than the article's 'not a cause for concern' dismissal."
The article frames Cho's sale as benign—Rule 10b5-1 plan, tax withholding, stock up 131.5%—but buries the real signal: he sold 10.58% of holdings at the peak, his largest single transaction in two years. TWST trades at ~$66.87 with TTM net loss of $81.28M on $409M revenue. The company is unprofitable and burning cash. Yes, Q2 revenue grew 19% YoY and guidance raised to 17-19% growth, but synthetic biology remains speculative. An insider dumping at a 52-week high after massive appreciation, even via a plan, warrants scrutiny—especially when the company hasn't demonstrated a path to profitability.
Rule 10b5-1 plans are specifically designed to eliminate timing-signal inference, and Cho retains $8M in direct holdings (0.19% of float), suggesting genuine conviction. The article's own data shows he's been steadily selling small amounts since Jan 2025, not panic-dumping.
"Financing risk (cash burn and potential equity raises) in a tiny float poses a bigger downside than the timing of Cho's large sale."
Responding to Gemini: The sell-the-news read is plausible, but the signal is muddied by timing. Cho's 14,205-share sale is 10.58% of his direct stake but the plan was set over a year ago; this isn't a naked panic. The bigger risk is ongoing cash burn and potential equity raises in a tiny float, which could crush the multiple regardless of an immediate earnings beat. Bottom line: don't ignore financing risk.
"The market's valuation of TWST is unsustainable due to high cash burn and interest rate pressures, rendering insider selling signals secondary to fundamental solvency risks."
Gemini, your 'sell the news' narrative ignores the structural reality of biotech equity compensation. When an executive's net worth is tied to a high-beta stock like TWST, a 10b5-1 plan is a risk-management tool, not a market-timing signal. The real danger isn't the CLO's exit; it's the 10x price-to-sales multiple in a high-rate environment. If the cost of capital stays elevated, the market will punish this cash-burning model regardless of insider activity.
"Post-sale insider ownership at 0.19% plus RSU dilution creates sustained overhang the 10x multiple can't absorb if growth slips."
Gemini correctly flags the 10x sales multiple but misses how Cho's exit leaves just 0.19% insider ownership, amplifying any future RSU dilution or secondary offerings. With $81M TTM losses and cash burn, even modest misses on the raised 17-19% guidance could trigger equity raises that crush the multiple faster than rate changes alone. The plan's age doesn't erase the structural overhang from repeated small sales.
"Insider ownership levels are a symptom of dilution risk, not a cause—the real signal is whether TWST's cash runway forces a raise in the next 12-18 months."
Grok conflates two separate risks. The 0.19% insider ownership is low, yes—but that's post-sale. The real question: does Cho's 10.58% trim signal he expects dilution ahead, or is it mechanical rebalancing after a 131.5% run? If TWST needs capital soon, the market will price it in regardless. The insider overhang matters only if future raises are imminent. Nobody's checked the balance sheet cash position or runway.
The panel consensus is bearish, with concerns over the company's profitability, high valuation, and potential dilution risk from equity raises. The insider sale, while planned, is seen as a red flag given the company's recent run-up and persistent losses.
Potential dilution risk from equity raises in a tiny float, which could crush the multiple regardless of an immediate earnings beat.